3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Anorexia
5
Neoplasms
4
Weight Loss
2
Pancreatic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Cachexia
2
Breast Neoplasms
2
Sleep Initiation and Maintenance Disorders
1
Neoplasm Metastasis
1
Malnutrition
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Depressive Disorder, Major
1
Depression
1
Body Weight
1
Anorexia Nervosa with Significantly Low Body Weight
1
Advanced Cancer
1
Interventions
Nivolumab
20
Ipilimumab
10
Paclitaxel
7
linrodostat
6
Standard of Care
6
Sirolimus
5
Gemcitabine
5
Bevacizumab
5
temsirolimus
4
relatlimab
4
Pemetrexed
4
Docetaxel
4
Carboplatin
4
ARRY-334543
4
Vorinostat
3
Erlotinib Hydrochloride
3
Dasatinib
3
Cetuximab
3
regorafenib
2
olaparib
2
apatinib
2
anlotinib
2
abemaciclib
2
Trastuzumab
2
Surveys and Questionnaires
2
Sunitinib
2
Sorafenib
2
Olanzapine
2
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
2
Magnetic Resonance Spectroscopy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Cancer
×
Mirtazapine
×
Clear all
NCT03254173
2020-02-05
MCACS100
Kasr El Aini Hospital
Phase 2/3
Completed
120 enrolled